Research progress of biomarkers of hepatitis B virus and clinical significance.
10.7507/1001-5515.202309041
- Author:
Xin WANG
1
;
Xiaoqiong TANG
1
;
Ning HAN
1
;
Hong TANG
1
Author Information
1. Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, P. R. China.
- Publication Type:Journal Article
- Keywords:
Biomarkers;
HBV RNA;
HBcrAg;
Hepatitis B virus
- MeSH:
Humans;
Hepatitis B virus/genetics*;
Clinical Relevance;
Hepatitis B, Chronic/drug therapy*;
Hepatitis B Core Antigens/therapeutic use*;
Biomarkers;
Liver Cirrhosis/drug therapy*;
Antiviral Agents/therapeutic use*;
Hepatitis B Surface Antigens/therapeutic use*;
DNA, Viral/therapeutic use*;
Hepatitis B e Antigens/therapeutic use*;
Hepatitis B/drug therapy*
- From:
Journal of Biomedical Engineering
2023;40(6):1242-1248
- CountryChina
- Language:Chinese
-
Abstract:
The infection of Hepatitis B virus (HBV) can result in severe consequences, including chronic hepatitis, liver fibrosis, cirrhosis, and even liver cancer. Effective antiviral treatment has the potential to slow down the progression of the disease. HBV serum biomarkers play a crucial role in the dynamic management of chronic hepatitis B (CHB) patients. However, the conventional hepatitis B virus markers, such as hepatitis B serologic testing and HBV DNA, are insufficient to meet the clinical requirements. This review provided a comprehensive overview of the current research on the quantification of HBsAg and anti-HBc, HBV RNA and HBV core-associated antigen, which summarized the crucial role these markers play in the administration of antiviral medications, predicting the efficacy of treatment and anticipating the likelihood of virologic rebound following drug cessation, as well as assessing disease progression in CHB patients.
